NewAmsterdam Pharma Company N.V. (NAMS)
(Delayed Data from NSDQ)
$21.28 USD
-0.53 (-2.43%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $21.25 -0.03 (-0.14%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth B Momentum F VGM
Fundamental Charts
About Return on Equity (TTM)
NewAmsterdam Pharma Company N.V.'s return on equity, or ROE, is -37.34% compared to the ROE of the Medical - Drugs industry of -57.32%. While this shows that NAMS has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
NAMS 21.28 -0.53(-2.43%)
Will NAMS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for NAMS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NAMS
Wall Street Analysts Predict a 132.5% Upside in NewAmsterdam Pharma Company N.V. (NAMS): Here's What You Should Know
NewAmsterdam Pharma Company N.V. (NAMS) Reports Q1 Loss, Tops Revenue Estimates
NAMS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Akebia Therapeutics (AKBA) Q1 Earnings and Revenues Top Estimates
Other News for NAMS
RA CAPITAL MANAGEMENT, L.P. Acquires 2,122,000 Shares in Contineum Therapeutics Inc
NewAmsterdam Pharma's Obicetrapib Shows Promise in Alzheimer's Biomarker Reduction | NAMS stock news
NewAmsterdam Pharma (NAMS) Releases Alzheimer's Biomarker Data from BROADWAY Trial
NewAmsterdam Pharma Presents Positive Data from BROADWAY Trial Demonstrating Statistically ...
NewAmsterdam Pharma presents data from BROADWAY trial at AAIC